lapatinib has been researched along with digoxin in 7 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (digoxin) | Trials (digoxin) | Recent Studies (post-2010) (digoxin) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 11,483 | 958 | 1,289 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Abbara, C; Bonhomme-Faivre, L; Chu, C; Farinotti, R; Gonin, P; Noël-Hudson, MS; Thomas-Bourgneuf, L | 1 |
| Arya, N; Bang, YJ; Beyer, J; Botbyl, J; Briley, LP; Cartee, L; Chu, Q; Chung, HC; Dar, MM; Koch, KM; Smith, DA; White, JH | 1 |
1 review(s) available for lapatinib and digoxin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for lapatinib and digoxin
| Article | Year |
|---|---|
Effect of lapatinib on oral digoxin absorption in patients.
Topics: Administration, Oral; Adult; Alberta; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cardiotonic Agents; Cross-Over Studies; Digoxin; Drug Interactions; Female; Gastrointestinal Absorption; Half-Life; Humans; Lapatinib; Metabolic Clearance Rate; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Seoul | 2015 |
5 other study(ies) available for lapatinib and digoxin
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Blotting, Western; Digoxin; Everolimus; Female; Intestinal Mucosa; Intestines; Lapatinib; Mice; Mice, Knockout; Quinazolines; Sirolimus; Substrate Specificity; Tissue Distribution | 2009 |